393 related articles for article (PubMed ID: 18405385)
1. The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs.
Chen CL; Chen L; Yang WC
BMC Public Health; 2008 Apr; 8():118. PubMed ID: 18405385
[TBL] [Abstract][Full Text] [Related]
2. Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan.
Huang SH; Hsu CN; Yu SH; Cham TM
BMC Public Health; 2012 May; 12():288. PubMed ID: 22521158
[TBL] [Abstract][Full Text] [Related]
3. Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003.
Lee YC; Yang MC; Huang YT; Liu CH; Chen SB
Pharmacoeconomics; 2006; 24(9):891-902. PubMed ID: 16942123
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
5. The evolution of Taiwan's National Health Insurance drug reimbursement scheme.
Hsu JC; Lu CY
Daru; 2015 Feb; 23(1):15. PubMed ID: 25889754
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
[TBL] [Abstract][Full Text] [Related]
7. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study.
Hsu JC; Lu CY; Wagner AK; Chan KA; Lai MS; Ross-Degnan D
Health Policy; 2014 Jun; 116(2-3):196-205. PubMed ID: 24314624
[TBL] [Abstract][Full Text] [Related]
8. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?
Kalaba M; Godman B; Vuksanović A; Bennie M; Malmström RE
J Comp Eff Res; 2012 Nov; 1(6):539-49. PubMed ID: 24236473
[TBL] [Abstract][Full Text] [Related]
9. ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008.
Bian B; Kelton CM; Guo JJ; Wigle PR
J Manag Care Pharm; 2010; 16(9):671-9. PubMed ID: 21067253
[TBL] [Abstract][Full Text] [Related]
10. Price regulation, new entry, and information shock on pharmaceutical market in Taiwan: a nationwide data-based study from 2001 to 2004.
Hsiao FY; Tsai YW; Huang WF
BMC Health Serv Res; 2010 Jul; 10():218. PubMed ID: 20653979
[TBL] [Abstract][Full Text] [Related]
11. Patterns of prescription antihypertensive drug utilization and adherence to treatment guidelines in the city of Novi Sad.
Tomas A; Tomić Z; Milijasević B; Ban M; Horvat O; Vukmirović S; Sabo A
Vojnosanit Pregl; 2016 Jun; 73(6):531-7. PubMed ID: 27498444
[TBL] [Abstract][Full Text] [Related]
12. The impact of nonreferral outpatient co-payment on medical care utilization and expenditures in Taiwan.
Chen LC; Schafheutle EI; Noyce PR
Res Social Adm Pharm; 2009 Sep; 5(3):211-24. PubMed ID: 19733822
[TBL] [Abstract][Full Text] [Related]
13. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
14. [Partial reimbursement of prescription charges for generic drugs reduces costs for both health insurance and patients].
Gouya G; Reichardt B; Bidner A; Weissenfels R; Wolzt M
Wien Klin Wochenschr; 2008; 120(3-4):89-95. PubMed ID: 18322770
[TBL] [Abstract][Full Text] [Related]
15. Managing health expenditure inflation under a single-payer system: Taiwan's National Health Insurance.
Yip WC; Lee YC; Tsai SL; Chen B
Soc Sci Med; 2019 Jul; 233():272-280. PubMed ID: 29548564
[TBL] [Abstract][Full Text] [Related]
16. Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study.
Cobiac LJ; Magnus A; Barendregt JJ; Carter R; Vos T
BMC Public Health; 2012 Jun; 12():398. PubMed ID: 22657090
[TBL] [Abstract][Full Text] [Related]
17. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea.
Bae G; Park C; Lee H; Han E; Kim DS; Jang S
BMC Health Serv Res; 2014 Mar; 14():100. PubMed ID: 24589172
[TBL] [Abstract][Full Text] [Related]
18. Doctor pharmaceutical utilization behaviour changed by the global budget programme strategies on hypertensive outpatient prescription.
Wei CK; Wang SM; Yeh MK
J Eval Clin Pract; 2012 Apr; 18(2):262-8. PubMed ID: 21040251
[TBL] [Abstract][Full Text] [Related]
19. Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.
Wouters OJ; Kanavos PG; McKEE M
Milbank Q; 2017 Sep; 95(3):554-601. PubMed ID: 28895227
[TBL] [Abstract][Full Text] [Related]
20. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]